By Eric D. Peterson, MD, MPH, FAHA, Committee on Scientific Sessions Program Chair
It’s the final day of Scientific Sessions! Over the past four days, we’ve heard exciting reports on important breakthroughs in research. Additionally, we learned about novel advances in clinical care, many of which can immediately impact how we treat our patients. And there is more to come today!
Today’s program includes the week’s final Late-Breaking Science session, “Innovative Therapies and Novel Applications,” which begins at 9 a.m. The session will feature the latest results from the REDUCE LAP-HF, TNT-POAF, PROPEL, ALLSTAR and HOPE-Duchenne trials. The presentations feature novel findings in the fields of preventive therapies, heart failure, atrial fibrillation, peripheral artery disease, myocardial infarction and Duchenne cardiomyopathy.
The schedule also includes three Main Event sessions highlighting the hottest research in population, basic and clinical science that was presented over the past four days at Scientific Sessions. Each session offers a unique opportunity to hear commentary from international leaders.
The first of these sessions, “Trending Topics in Population Science,” begins at 9 a.m. in Ballroom A, 3rd Level, Main Building. “Trending Topics in Basic Science” and “Trending Topics in Clinical Science” run concurrently at 10:45 a.m. in Ballroom A and Ballroom CD, respectively.
Before we adjourn today and head back to our practices, hospitals, clinics and labs, I want to thank my fellow members of the Committee on Scientific Sessions Program for putting together an outstanding educational program. I must also thank the AHA staff for their dedication and exceptional efforts in maintaining the Scientific Sessions’ reputation as the world’s premier meeting in cardiovascular science and medicine.
And finally, I want to thank all of my colleagues and friends who attended this year’s meeting. I look forward to seeing all of you again next year at the 2018 Scientific Sessions in Chicago, Nov. 10-14.
Late-Breaking Science VII: Innovative Therapies and Novel Applications
LBS.07 | 9-10:15 a.m. Wednesday | Ballroom CD, 3rd Level, Main Building
|REDUCE LAP-HF — Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure: Results from the REDUCE LAP-HF I Randomized Controlled Trial||This trial was designed to evaluate the safety and effectiveness of the InterAtrial Shunt Device to lower LA pressure in patients with heart failure.|
|TNT-POAF — Temporary Neurotoxin Treatment to Prevent Postoperative Atrial Fibrillation||This trial was designed to assess the efficacy and safety of epicardial botulinum toxin injection to prevent atrial fibrillation after cardiac surgery.|
|PROPEL — Granulocyte Macrophage Colony-Stimulating Factor With and Without Supervised Exercise to Improve Walking Performance in Peripheral Artery Disease||This trial was designed to determine whether granulocyte-macrophage colony stimulating factor (GM-CSF) combined with supervised treadmill exercise improved walking performance more than GM-CSF alone and supervised exercise alone in PAD.|
|ALLSTAR — 6-Month Results of ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration Trial: A Randomized, Placebo-Controlled, Double-Blind Study||This trial evaluated the safety and efficacy of intracoronary allogeneic cardiac-derived stem cells in post-infarction patients.|
|HOPE-Duchenne — Cardiosphere-Derived Cells for the Treatment of Duchenne Cardiomyopathy: Results of the Halt cardiOmyopathy ProgrEssion-Duchenne Trial||The HOPE-Duchenne clinical trial was designed to evaluate the safety and efficacy of multivessel intracoronary delivery of allogeneic cardiosphere-derived cells in patients with cardiomyopathy secondary to Duchenne muscular dystrophy.|